Latest News

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Source link

Related posts

U.S. researcher says he’s ready to start four pregnancies with ‘three-parent’ embryos


Performance-enhancing with … potatoes!


Tackling unhealthy lifestyle factors could increase life expectancy of people with severe mental illness


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy